TenNor Completed 264 million RMB Series D Financing

TENNOR DISCLOSES OF TNP-2198 FOR H. PYLORI INFECTIONS

TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia

TenNor Enters Research Collaboration with Janssen for Potential New Treatments for NTM Diseases

TenNor Initiated TNP-2198 Phase 1b/IIa Clinical Trials

TenNor presented Phase II results of TNP-2092 at 2020 CBIIC

TenNor Initiated Phase II Clinical Trial for Hepatic Encephalopathy

TenNor Named One of the Potential Unicorn Enterprises in Suzhou

TenNor Therapeutics Received FDA Orphan Drug Designation

©2013 TENNOR THERAPEUTICS LTD